Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40SY6 | ISIN: US53630L2097 | Ticker-Symbol:
NASDAQ
05.06.25 | 22:00
3,080 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
LIPELLA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
LIPELLA PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur LIPELLA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiLipella Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite3
MiLipella Pharmaceuticals extends manufacturing pact with Cook MyoSite1
MiLipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development63PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases...
► Artikel lesen
15.05.LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report1
14.05.LIPELLA PHARMACEUTICALS INC. - 10-Q, Quarterly Report1
22.04.Lipella Pharmaceuticals Inc.: Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 202573Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward...
► Artikel lesen
LIPELLA PHARMACEUTICALS Aktie jetzt für 0€ handeln
14.04.LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report3
08.04.Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus113PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies...
► Artikel lesen
07.04.LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report1
31.03.Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast1
11.03.LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report1
03.03.LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report-
24.02.LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report-
11.02.Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes2
11.02.LIPELLA PHARMACEUTICALS INC. - 8-K, Current Report-
11.02.Pre-market Movers: Lipella Pharmaceuticals, Vast Renewables, Fluence Energy, SelectQuote, Harmonic550CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.10 A.M. ET).In the Green Lipella Pharmaceuticals Inc. (LIPO) is up over 62%...
► Artikel lesen
11.02.Lipella Pharma Reports Positive Phase 2a Data For LP-310 In Oral Lichen Planus; Stock Up8
11.02.Lipella Pharmaceuticals Inc.: Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus140LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily...
► Artikel lesen
06.02.Pre-market Movers: Lipella Pharmaceuticals, Invivyd, Beasley Broadcast Group, Pasithea Therapeutics, Skyworks Solutions690OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.55 A.M. ET).In the Green Lipella Pharmaceuticals Inc. (LIPO) is up over 180%...
► Artikel lesen
06.02.FDA genehmigt Lipella's Programm für orales Behandlungsverfahren18
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1